Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer

doi:10.4240/wjgs.v15.i5.906

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2153)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1159

Figures (1-1)

130

Tables (1-5)

152

Sum=1544

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

118

Download

491

Sum=609

May 27, 2023 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. May 27, 2023; 15(5): 906-916
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906

Table 4 Comparison of tumor marker levels between the two groups

Group	HE4 (pmol/L)		CA125 (ng/mL)		CA199 (U/mL)
Group	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 43), mean ± SD	343.75 ± 51.26	184.65 ± 22.34^a	82.43 ± 11.27	58.56 ± 6.08^a	119.60 ± 15.62	82.84 ± 9.28^a
Observation group (n = 39), mean ± SD	349.81 ± 45.79	121.36 ± 19.48^a	83.26 ± 10.33	35.61 ± 4.25^a	121.03 ± 19.85	56.37 ± 7.41^a
t	0.562	13.610	0.346	19.618	0.364	14.177
P value	0.576	< 0.001	0.730	< 0.001	0.717	< 0.001

^aP < 0.05 vs before treatment in the same group. HE4: Human epididymis protein 4; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199.

Citation: Jiang YL, Fu XY, Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15(5): 906-916
URL: https://www.wjgnet.com/1948-9366/full/v15/i5/906.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i5.906